A study of steroid-induced diabetes mellitus in leprosy

Indian Journal of Leprosy

Volumn 81, Issue 3, 2009, Pages 125-129

  Papang, R ^a   John, A S ^a   Abraham, S ^b   Rao, P S S S ^c  

^a TLM Hospital   (India)

^b TLM Community Hospital   (India)

^c India   (India)

Author keywords

Leprosy; NSID; SID

Indexed keywords

GLUCOSE; PREDNISOLONE; GLUCOCORTICOID;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DRUG INDUCED DISEASE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INDIA; LEPROSY; MAJOR CLINICAL STUDY; MALE; NEURITIS; POSTPRANDIAL STATE; PROSPECTIVE STUDY; SCHOOL CHILD; STEROID INDUCED DIABETES MELLITUS; TEST STRIP; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; FOLLOW UP; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INDIA; LEPROSY; MALE; MIDDLE AGED; PREDNISOLONE; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77953992492     PISSN: 02549395     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Agarwal DK, Jeloka T, Sharma AP et al (2002). Steroid induced diabetes mellitus presenting as diabetic ketoacidosis. Indian J Nephrol. 12: 122-123.
2. Athreya SPK (2007). Azathioprine in controlling type 2 reaction in leprosy : a case report. Lepr Rev.78:290-292.
3. Bjelakovic G, Beninati S, Pavlovic D et al (2007). Glucocorticoids and oxidative stress. J Basic Clin Physiol Pharmacol. 18:115-127.
4. Britton WJ (1998). The management of leprosy reversal reactions. Lepr Rev. 69:225-234.
5. Croft RP, Nicholls PG, Richardus JH et al (2000). The treatment of acute nerve function impairment in leprosy: results from a prospective cohort study in Bangladesh. Lepr Rev. 71:154-168.
6. Dendukuri N, Blais L and LeLorier J (2002). Inhaled corticosteroids and the risk of diabetes among the elderly. Br J Clin Pharmacol. 54: 59-64.
7. Edward VK (1995). Diabetic ketoacidosis following steroid therapy in a rural leprosy hospital. Int J Lepr Other Mycobact Dis. 63: 289-291.
8. Girdhar BK, Girdhar A and Chakma JK (2007). Advances in the treatment of reactions in leprosy. Indian J Lepr. 79:121-134.
9. Lockwood DN (1996). The management of erthema nodosum leprosum: current and future options. Lepr Rev.67: 253-259.
10. Lockwood D and Bryceson A (2003). The return of thalidomide: new uses and renewed concerns. Lepr Rev. 74: 290-294.
11. Mahajan VK, Sharma NL, Sharma RC et al (2003). Pulse dexamethasone, oral steroids and azathioprine in the management of erythema nodosum leprosum. Lepr Rev. 74: 171-174.
12. Mohan V, Deepa M, Deepa R et al (2006). Secular trends in the prevalence of diabetes and impaired glucose tolerance in urban South India - the Chennai Urban Rural Epidemiology Study (CURES-17). Diabetologia. 49: 1175-1178.
13. Mohan V, Radhika G, Sathya RM et al (2009). Dietary carbohydrates, glycaemic load, food groups and newly detected type 2 diabetes among urban Asian Indian population in Chennai, India (Chennai Urban Rural Epidemiology Study 59). Br J Nutr. 9:1-9.
14. Pai VV, Bulchand HO, Dandekar A et al (2002). Screening for diabetes in reaction patients. Indian J Lepr. 74:75.
15. Powers AC (2005). Diabetes Mellitus. In Harrisons' Principles of Internal Medicine, 16th edn (Kasper DL, Braunwald E, Fauci AS et al, eds), McGraw Hill, New York, pp 2152- 2170.
16. Quiram PA, Gonzales CR and Schwartz SD (2006). Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide. Am J Ophthalmol. 141: 580-582.
17. Ramachandran A, Snehalatha C, Kapur A et al (2001). High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. Diabetologia. 44:1094-1101.
18. Rao PSS, Sugamaran DST, Richard J et al (2006). Multicentre, double blind, randomized trial of three steroid regimens in the treatment of type-1 reactions in leprosy. Lepr Rev. 77:25-33.
19. Richardus JH, Withington SG, Anderson AM et al (2003). Adverse events of standardized regimens of corticosteroids for prophylaxis and treatment of nerve function impairment in leprosy: results from the 'TRIPOD' trials. Lepr Rev. 74:319-327.
20. Roche PW, Theuvenet WJ, Le Master JW et al (1988). Contribution of type 1 reaction to sensory and motor function loss in borderline leprosy patients and the efficacy of treatment with prednisolone. Int J Lepr Other Mycobact Dis. 66: 340-347.
21. Sugumaran DST (1998) . Leprosy reactions-complications of steroid therapy. Int J Lepr Other Mycobact Dis. 66: 10-15.
22. Swartz SL and Dluhy RG (1978). Corticosteroids: clinical pharmacology and therapeutic use. Drugs. 16: 238-255. (Pubitemid 9001468)
23. van Brakel WH, Nicholls PG, Das L et al (2005). The INFIR cohort study: investigating prediction, detection and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in North India. Lepr Rev. 76:14-34.
24. van der Linden MW, Penning-van Beest FJA, Nijsten T et al (2009). Topical corticosteroids and the risk of diabetes mellitus: a nested case-control study in the Netherlands. Drug Saf. 32: 527-537.
25. van Raalte DH, Ouwens DM and Diamant M (2009). Novel insights into glucocorticoid-mediated diabetoenic effects : towards expansion of therapeutic options? Eur J Clin Invest. 39:81-93.
26. van Veen NH, Nicholls PG, Smith WCS et al (2008). Cortcosteroids for treating nerve damage in leprosy. A Cochrane review. Lepr Rev. 79: 361-367.
27. Walker SL, Waters MFR and Lockwood DNJ (2007). The role of thalidomide in the management of erythema nodosum leprosum. Lepr Rev. 78: 197-215.
28. World Health Organization (1998). Expert committee on leprosy. WHO, Geneva, Switzerland. Tech Rep Ser. 874: 1-43.
29. Zargar AH, Wani AI, Masoodi SR et al (2009). Causes of mortality in diabetes mellitus: data from a tertiary teaching hospital in India. Postgrad Med J. 85:227-232.